{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T08:01:10Z","timestamp":1779350470404,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,4,8]],"date-time":"2012-04-08T00:00:00Z","timestamp":1333843200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1007\/s10549-012-2041-5","type":"journal-article","created":{"date-parts":[[2012,4,8]],"date-time":"2012-04-08T05:38:44Z","timestamp":1333863524000},"page":"299-306","source":"Crossref","is-referenced-by-count":42,"title":["Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene"],"prefix":"10.1007","volume":"134","author":[{"given":"Trevor J.","family":"Powles","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan J.","family":"Diem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol J.","family":"Fabian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Neven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. Lawrence","family":"Wickerham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Muram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donato","family":"Agnusdei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherie A.","family":"Dowsett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Messan","family":"Amewou-Atisso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven R.","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,4,8]]},"reference":[{"key":"2041_CR1","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","volume":"90","author":"B Fisher","year":"1998","unstructured":"Fisher B, Costantino JP, Wickerham DL et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371\u20131388","journal-title":"J Natl Cancer Inst"},{"key":"2041_CR2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0140-6736(98)85011-3","volume":"352","author":"U Veronesi","year":"1998","unstructured":"Veronesi U, Maisonneuve P, Costa A et al (1998) Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 352:93\u201397","journal-title":"Lancet"},{"key":"2041_CR3","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0140-6736(98)05071-5","volume":"352","author":"T Powles","year":"1998","unstructured":"Powles T, Eeles R, Ashley S et al (1998) Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352:98\u2013101","journal-title":"Lancet"},{"key":"2041_CR4","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(02)09962-2","volume":"360","author":"J Cuzick","year":"2002","unstructured":"Cuzick J, Forbes J, Edwards R et al (2002) First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 360:817\u2013824","journal-title":"Lancet"},{"key":"2041_CR5","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","volume":"282","author":"B Ettinger","year":"1999","unstructured":"Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282:637\u2013645","journal-title":"JAMA"},{"key":"2041_CR6","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1001\/jama.281.23.2189","volume":"281","author":"SR Cummings","year":"1999","unstructured":"Cummings SR, Eckert S, Krueger KA et al (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. [see comment] [erratum appears in JAMA 1999;282(22):2124]. JAMA 281:2189\u20132197","journal-title":"JAMA"},{"key":"2041_CR7","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1634\/theoncologist.9-2-116","volume":"9","author":"S Martino","year":"2004","unstructured":"Martino S, Costantino J, McNabb M et al (2004) The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials. Oncologist 9:116\u2013125","journal-title":"Oncologist"},{"key":"2041_CR8","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","volume":"295","author":"VG Vogel","year":"2006","unstructured":"Vogel VG, Costantino JP, Wickerham DL et al (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes. JAMA 295:2727\u20132741","journal-title":"JAMA"},{"key":"2041_CR9","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1056\/NEJMoa0808692","volume":"362","author":"SR Cummings","year":"2010","unstructured":"Cummings SR, Ensrud K, Delmas PD et al (2010) Lasofoxifene for postmenopausal women with osteoporosis. N Engl J Med 362:686\u2013696","journal-title":"N Engl J Med"},{"key":"2041_CR10","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1093\/jnci\/djq415","volume":"102","author":"A Croix La","year":"2010","unstructured":"La Croix A, Powles TJ, Osborn CK et al (2010) Breast cancer incidence in the PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J Natl Cancer Inst 102:1706\u20131715","journal-title":"J Natl Cancer Inst"},{"key":"2041_CR11","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1359\/jbmr.080710","volume":"23","author":"SL Silverman","year":"2008","unstructured":"Silverman SL, Christiansen C, Genant HK et al (2008) Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 23:1923\u20131934","journal-title":"J Bone Miner Res"},{"key":"2041_CR12","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/gme.0b013e3181a818db","volume":"16","author":"DF Archer","year":"2009","unstructured":"Archer DF, Pinkerton JV, Utian WH et al (2009) Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women. Menopause 16:1109\u20131115","journal-title":"Menopause"},{"key":"2041_CR13","first-page":"8412","volume":"61","author":"N Suh","year":"2001","unstructured":"Suh N, Glasebrook AL, Palkowitz AD et al (2001) Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer. Cancer Res 61:8412\u20138415","journal-title":"Cancer Res"},{"key":"2041_CR14","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1021\/jm970167b","volume":"40","author":"AD Palkowitz","year":"1998","unstructured":"Palkowitz AD, Glasebrook AL, Thrasher KJ, Hauser KL et al (1998) Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]benzothiophene: a novel, highly potent, selective estrogen receptor modulator. J Med Chem 40:1407\u20131416","journal-title":"J Med Chem"},{"key":"2041_CR15","first-page":"1","volume":"287","author":"M Sato","year":"1998","unstructured":"Sato M, Turner CH, Wang T, Adrian MD et al (1998) LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo. J Pharmacol Exp Ther 287:1\u20137","journal-title":"J Pharmacol Exp Ther"},{"key":"2041_CR16","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1200\/JCO.2003.06.108","volume":"21","author":"A Buzdar","year":"2003","unstructured":"Buzdar A, O\u2019Shaughnessy JA, Booser DJ et al (2003) Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. J Clin Oncol 21:1007\u20131014","journal-title":"J Clin Oncol"},{"key":"2041_CR17","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/annonc\/mdg368","volume":"14","author":"J Baselga","year":"2003","unstructured":"Baselga J, Llombart-Cussac A, Bellet M et al (2003) Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients. Ann Oncol 14:1383\u20131390","journal-title":"Ann Oncol"},{"key":"2041_CR18","doi-asserted-by":"crossref","first-page":"4967","DOI":"10.1200\/JCO.2006.09.5992","volume":"25","author":"V Deshmane","year":"2007","unstructured":"Deshmane V, Krishnamurthy S, Melemed AS, Peterson P, Buzdar AU (2007) Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer. J Clin Oncol 25:4967\u20134973","journal-title":"J Clin Oncol"},{"key":"2041_CR19","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1158\/1078-0432.CCR-04-0171","volume":"10","author":"CJ Fabian","year":"2004","unstructured":"Fabian CJ, Kimler BF, Anderson J et al (2004) Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator. Clin Cancer Res 10:5403\u20135417","journal-title":"Clin Cancer Res"},{"key":"2041_CR20","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/jbmr.191","volume":"26","author":"SR Cummings","year":"2011","unstructured":"Cummings SR, McClung M, Reginster JY et al (2011) Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women. J Bone Miner Res 26:397\u2013404","journal-title":"J Bone Miner Res"},{"key":"2041_CR21","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1093\/jnci\/81.24.1879","volume":"81","author":"MH Gail","year":"1989","unstructured":"Gail MH, Brinton LA, Byar DP et al (1989) Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81:1879\u20131886","journal-title":"J Natl Cancer Inst"},{"key":"2041_CR22","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S0140-6736(03)12342-2","volume":"361","author":"J Cuzick","year":"2003","unstructured":"Cuzick J, Powles T, Veronesi U et al (2003) Overview of the main outcomes in breast-cancer prevention trials. Lancet 361:296\u2013300","journal-title":"Lancet"},{"key":"2041_CR23","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1158\/1940-6207.CAPR-10-0076","volume":"3","author":"VG Vogel","year":"2010","unstructured":"Vogel VG, Costantino JP, Wickerham DL et al (2010) Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res 3:696\u2013706","journal-title":"Cancer Prev Res"},{"key":"2041_CR24","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/jnci\/djk049","volume":"99","author":"J Cuzick","year":"2007","unstructured":"Cuzick J, Forbes JF, Sestak I et al (2007) Long-term results of tamoxifen prophylaxis for breast cancer\u201396-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 99:272\u2013282","journal-title":"J Natl Cancer Inst"},{"key":"2041_CR25","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/jnci\/djk050","volume":"99","author":"TJ Powles","year":"2007","unstructured":"Powles TJ, Ashley S, Tidy A et al (2007) Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 99:283\u2013290","journal-title":"J Natl Cancer Inst"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-012-2041-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-012-2041-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-012-2041-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T16:34:01Z","timestamp":1559234041000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-012-2041-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,8]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["2041"],"URL":"https:\/\/doi.org\/10.1007\/s10549-012-2041-5","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,8]]}}}